| 1 |
dpavlin |
1.1 |
<p align="center"><font face="Arial" size="2" color="#000080"><b><br> |
| 2 |
|
|
PLIVA d.d. General Assembly Held Today</b></font></p> |
| 3 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">Zagreb, 8 June |
| 4 |
|
|
2000 - the General Assembly of PLIVA d.d. shareholders was held today. The |
| 5 |
|
|
PLIVA Management Board presented Company's 1999 operations and position, |
| 6 |
|
|
while the Supervisory Board gave a presentation on their monitoring of the |
| 7 |
|
|
Company's management of affairs.</font></p> |
| 8 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">PLIVA's strong expansion |
| 9 |
|
|
persisted throughout 1999. Compared with 1998, revenues rose by 16.9 % to |
| 10 |
|
|
HRK 4,180.5 m., of which 65.5 % were recorded on international markets. |
| 11 |
|
|
Earnings before interest and taxes (EBIT) recorded a 27.3% growth to HRK |
| 12 |
|
|
1,079.4 m., and the Company's net profit reached HRK 869 m. Profit per |
| 13 |
|
|
share was up 27.8% to HRK 44.17.<br> |
| 14 |
|
|
PLIVA furthered its internationalization with the acquisitions of three |
| 15 |
|
|
pharmaceutical companies: FARMACOM, MIXIS Genetics and LACHEMA, thereby |
| 16 |
|
|
reinforcing PLIVA's position in its target markets. The year 1999 was also |
| 17 |
|
|
marked by strong investments and a 46.5 percent growth in R&D |
| 18 |
|
|
spending.</font></p> |
| 19 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">The following distribution |
| 20 |
|
|
of 1999 net income (HRK 838.5 m.) was proposed in the General Assembly |
| 21 |
|
|
agenda:</font></p> |
| 22 |
|
|
<ul> |
| 23 |
|
|
<li> |
| 24 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">HRK 2.3 m. to legal |
| 25 |
|
|
reserves,</font></li> |
| 26 |
|
|
<li> |
| 27 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">a declared dividend of |
| 28 |
|
|
HRK 10.00 per share to be paid out to all shareholders registered with |
| 29 |
|
|
the Central Depository Agency on the decision date (to be paid out |
| 30 |
|
|
before 31 December 2000). The HRK 10.00 dividend per share represents |
| 31 |
|
|
a 36.1% increase over last year's dividend.</font></li> |
| 32 |
|
|
<li> |
| 33 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">the remainder of the |
| 34 |
|
|
income to be transferred to retained earnings.</font></li> |
| 35 |
|
|
</ul> |
| 36 |
|
|
<p align="justify"><font face="Arial" size="2" color="#000080">Commenting on the 1999 |
| 37 |
|
|
business results, Mr. Zeljko Covic, President of PLIVA's Management Board, |
| 38 |
|
|
said: "PLIVA has retained its position as the leading CEE and largest |
| 39 |
|
|
Croatian pharmaceutical company. The cornerstone of PLIVA's business |
| 40 |
|
|
orientation, as well as its future, resides in its business policy of |
| 41 |
|
|
continuous global market growth and development, the strategic focus on |
| 42 |
|
|
pharmaceuticals, an increase in share capital value, consistent |
| 43 |
|
|
investments in state-of-the-art technology and new product research & |
| 44 |
|
|
development".</font></p> |
| 45 |
|
|
<p><font face="Arial" size="2" color="#000080"><i>PLIVA d.d. Management |
| 46 |
|
|
Board members are:</i><b><br> |
| 47 |
|
|
</b><br> |
| 48 |
|
|
<b>Zeljko Covic</b>, MSc, President & CEO<br> |
| 49 |
|
|
<b>Erika Kaspar</b>, MSc, Vice-President & Director of Corporate |
| 50 |
|
|
Affairs and<br> |
| 51 |
|
|
Communications<br> |
| 52 |
|
|
<b>Radan Spaventi</b>, MD, PhD, Vice-President & CSO<br> |
| 53 |
|
|
<b>Dubravko Mak</b>, Vice-President & COO<br> |
| 54 |
|
|
<b>Zeljko Peric</b>, Vice-President & CFO<br> |
| 55 |
|
|
<br> |
| 56 |
|
|
<br> |
| 57 |
|
|
<i>PLIVA d.d. Supervisory Board members are:</i><b><br> |
| 58 |
|
|
</b><br> |
| 59 |
|
|
<b>Massimo Armanini</b>, MBA, President of the Supervisory Board, |
| 60 |
|
|
EUROPORTAL ITALIA S.p.A., Member of GRUPPO FININVEST<br> |
| 61 |
|
|
<b>Branko Jeren</b>, PhD, Vice-President of the Supervisory Board, |
| 62 |
|
|
University of Zagreb<br> |
| 63 |
|
|
<b>Zdenko Adrovic</b>, Raiffeisenbank Austria d.d.<br> |
| 64 |
|
|
<b>David Bloom</b>, PhD, David Bloom and Associates<br> |
| 65 |
|
|
<b>Ettore dell'Isola</b>, PhD, MBA, European Vinyls Corporation<br> |
| 66 |
|
|
<b>Lindsay M. Forbes</b>, MBA, EBRD<br> |
| 67 |
|
|
<b>Franjo Lukovic</b>, Zagrebacka Banka d.d.<br> |
| 68 |
|
|
<b>Ivan Mijatovic</b>, Ministry of Finance, Croatia<br> |
| 69 |
|
|
<b>Mr. Martin Pastuovic</b>, PLIVA d.d.</font></p> |
| 70 |
|
|
<p align="center"><font face="Arial" size="2" color="#000080"><b>PLIVA |
| 71 |
|
|
d.d. OWNERSHIP STRUCTURE<br> |
| 72 |
|
|
as at 8 June 2000<br> |
| 73 |
|
|
<br> |
| 74 |
|
|
<br> |
| 75 |
|
|
<img border="0" src="../images/SkupstinaChart.gif" width="400" height="345"></b></font></p> |
| 76 |
|
|
<p align="left"><font face="Arial" size="2" color="#000080"><br> |
| 77 |
|
|
For further information, please contact:</font></p> |
| 78 |
|
|
<table border="0" cellpadding="0" cellspacing="0" width="100%"> |
| 79 |
|
|
<tr> |
| 80 |
|
|
<td width="50%" valign="top" align="left"><font face="Arial" size="2" color="#000080"><b>Ms. |
| 81 |
|
|
Dijana Kobas</b><br> |
| 82 |
|
|
Corporate Communications<br> |
| 83 |
|
|
Phone: 01 / 61 20 852<br> |
| 84 |
|
|
Fax: 01 / 61 60 358<br> |
| 85 |
|
|
e-mail: <a href="mailto:Dijana.Kobas@pliva.hr">Dijana.Kobas@pliva.hr<br> |
| 86 |
|
|
</a></font></td> |
| 87 |
|
|
</tr> |
| 88 |
|
|
</table> |
| 89 |
|
|
<p align="center"><font face="Arial" size="2" color="#000080"><b>PLIVA's Vision:<br> |
| 90 |
|
|
<br> |
| 91 |
|
|
To be a pharmaceutical company bringing superior and innovative |
| 92 |
|
|
solutions to customer needs, by competing in the global market. |
| 93 |
|
|
</b></font></p> |
Parent Directory
| 
Revision Log